Pacira BioSciences (PCRX) announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company’s Board of Directors to 10 members. Most recently, Dr. Hirawat served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb (BMY).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira announces agreement with LG Chem
- Pacira management to meet with H. C. Wainwright
- Pacira Biosciences: Exparel-Led Growth and Discounted Valuation Support Attractive Risk–Reward and Buy Rating
- Pacira: Maintaining Buy on Durable Non-Opioid Growth and Share Buybacks Despite Near-Term Revenue Softness
- Closing Bell Movers: AXT Inc. slips after cutting Q4 revenue guidance